Corporate$IMVT10:19 AM ET

Immunovant trial for IMVT-1402 in CLE misses primary endpoint

By BORSA NewsroomPublished Sep 23, 2026, 10:19 AM EDTUpdated Sep 25, 2026, 12:48 PM EDT

Immunovant said its proof-of-concept trial for IMVT-1402 in cutaneous lupus erythematosus did not achieve statistical significance on the primary endpoint. The company plans to stop development in CLE but will continue in other autoimmune diseases. Stock down 5%.

Sentimentbearish 35

Bearish · 35 of 100

Impact30

low · stays off the top drivers

Confidence90%

high confidence · single wire

Eventdeveloping

v1 · alerts feed only

WHAT WE KNOW

Proof-of-concept trial for IMVT-1402 in CLE missed primary endpoint.